Fosalvudine tidoxil

Cat. No.: HY-14922

CAS No.: 763903-67-9

Molecular Formula: $C_{35}H_{64}FN_2O_8PS$

Molecular Weight: 722.93

Target: Reverse Transcriptase; HIV

Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Fosalvudine tidoxil is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Fosalvudine tidoxil is a prodrug derived from Alovudine (HY-B1516). Fosalvudine tidoxil is less toxic than Alovudine and can be used for the research of HIV-1 infection[1].
IC_{50} & Target	Nucleoside reverse transcriptase[1]
In Vivo	Fosalvudine tidoxil (15-100 mg/kg/day; oral; 8 weeks) induces significant mitochondrial hepatotoxicity in rats[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley rats[1]
Dosage:	15, 40, or 100 mg/kg/day
Administration:	Oral gavage, 8 weeks
Result:	Induced significant mtDNA depletion. At doses of 15, 40, and 100 mg/kg, the mean hepatic mtDNA values were 62, 64, and 47% of control values, respectively.

REFERENCES

[1]. Venhoff AC, et al. Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. Antimicrob Agents Chemother. 2009 Jul;53(7):2748-51.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA